Interaction of Botulinum Type A, B and E Derivative Toxins with Synaptosomes of Rat Brain

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1979 Jul 31

PMID 492355

Citations 15

Authors

S Kozaki

Affiliations

Soon will be listed here.

Abstract

Clostridium botulimum 125I-labelled derivative toxin immediately bound to rat synaptosomes. Of the two fragments of type B derivative toxin, the large-molecular-weight fragment (fragment I) inhibited the binding of labelled type B derivative toxin to synaptosomes in the same manner as unlabelled type B toxin did. The inhibition by the small-molecular-weight fragment (fragment II) was less than that by fragment I. These findings suggest that type B toxin binds to synaptosomes mainly with some part of fragment I. The binding of labelled type A and E derivative toxins was inhibited by either of the unlabelled type A or E derivative toxins, but not by type B derivative toxin. It is concluded that synaptosomes of rat brain possess relatively specific binding sites for botulinum toxin types.

Citing Articles

Synaptotagmin II and gangliosides bind independently with botulinum neurotoxin B but each restrains the other.

Atassi M, Taruishi M, Naqvi M, Steward L, Aoki K Protein J. 2014; 33(3):278-88.

PMID: 24740609 DOI: 10.1007/s10930-014-9557-y.

Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions.

Atassi M, Dolimbek B, Steward L, Aoki K Protein J. 2010; 29(5):320-7.

PMID: 20571899 DOI: 10.1007/s10930-010-9255-3.

Botulinum neurotoxin - from laboratory to bedside.

Foster K, Bigalke H, Aoki K Neurotox Res. 2006; 9(2-3):133-40.

PMID: 16785110 DOI: 10.1007/BF03033931.

Characterization of Clostridium botulinum type B neurotoxin associated with infant botulism in japan.

Kozaki S, Kamata Y, Nishiki T, Kakinuma H, Maruyama H, Takahashi H Infect Immun. 1998; 66(10):4811-6.

PMID: 9746583 PMC: 108594. DOI: 10.1128/IAI.66.10.4811-4816.1998.

Expression of botulinum toxin binding sites in Xenopus oocytes.

Bakry N, Kamata Y, Simpson L Infect Immun. 1997; 65(6):2225-32.

PMID: 9169755 PMC: 175307. DOI: 10.1128/iai.65.6.2225-2232.1997.

References

Wonnacott S, Marchbanks R . Inhibition by botulinum toxin of depolarization-evoked release of (14C)acetylcholine from synaptosomes in vitro. Biochem J. 1976; 156(3):701-12. PMC: 1163806. DOI: 10.1042/bj1560701. View

Hirokawa N, Kitamura M . Localization of radioactive I25I-labelled botulinus toxin at the neuromuscular junction of mouse diaphragm. Naunyn Schmiedebergs Arch Pharmacol. 1975; 287(1):107-10. DOI: 10.1007/BF00632642. View

Dasgupta B, Sugiyama H . A common subunit structure in Clostridium botulinum type A, B and E toxins. Biochem Biophys Res Commun. 1972; 48(1):108-12. DOI: 10.1016/0006-291x(72)90350-6. View

Miyazaki S, Iwasaki M, Sakaguchi G . Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties. Infect Immun. 1977; 17(2):395-401. PMC: 421134. DOI: 10.1128/iai.17.2.395-401.1977. View

Sakaguchi G, Sakaguchi S, Kondo H . Rapid bioassay for Clostridium botulinum type-E toxins by intravenous injection into mice. Jpn J Med Sci Biol. 1968; 21(6):369-78. DOI: 10.7883/yoken1952.21.369. View

Beers W, Reich E . Isolation and characterization of Clostridium botulinum type B toxin. J Biol Chem. 1969; 244(16):4473-9. View

Lamanna C, Sakaguchi G . Botulinal toxins and the problem of nomenclature of simple toxins. Bacteriol Rev. 1971; 35(3):242-9. PMC: 378388. DOI: 10.1128/br.35.3.242-249.1971. View

Kitamura M, Sakaguchi S, Sakaguchi G . Purification and some properties of Clostridium botulinum type-E toxin. Biochim Biophys Acta. 1968; 168(2):207-17. DOI: 10.1016/0005-2795(68)90144-x. View

BOROFF D, Fleck U . Statistical analysis of a rapid in vivo method for the titration of the toxin of Clostridium botulinum. J Bacteriol. 1966; 92(5):1580-1. PMC: 276463. DOI: 10.1128/jb.92.5.1580-1581.1966. View

10.

Kozaki S, Sakaguchi G . Antigenicites of fragments of Clostridium botulinum type B derivative toxin. Infect Immun. 1975; 11(5):932-6. PMC: 415160. DOI: 10.1128/iai.11.5.932-936.1975. View

11.

Kitamura M . Binding of botulinum neurotoxin to the synaptosome fraction of rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1976; 295(2):171-5. DOI: 10.1007/BF00499451. View

12.

Yang K, Sugiyama H . Purification and properties of Clostridium botulinum type F toxin. Appl Microbiol. 1975; 29(5):598-603. PMC: 187043. DOI: 10.1128/am.29.5.598-603.1975. View

13.

BURGEN A, DICKENS F, ZATMAN L . The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949; 109(1-2):10-24. PMC: 1392572. DOI: 10.1113/jphysiol.1949.sp004364. View

14.

Sugii S, Sakaguchi G . Molecular construction of Clostridium botulinum type A toxins. Infect Immun. 1975; 12(6):1262-70. PMC: 415430. DOI: 10.1128/iai.12.6.1262-1270.1975. View

15.

Whittaker V . The isolation and characterization of acetylcholine-containing particles from brain. Biochem J. 1959; 72:694-706. PMC: 1196995. DOI: 10.1042/bj0720694. View

16.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

17.

Bigalke H, Dimpfel W, Habermann E . Suppression of 3H-acetylcholine release from primary nerve cell cultures by tetanus and botulinum-A toxin. Naunyn Schmiedebergs Arch Pharmacol. 1978; 303(2):133-8. DOI: 10.1007/BF00508058. View

18.

OHISHI I, Sakaguchi G . Molecular construction of Clostridium botulinum type F progenitor toxin. Appl Microbiol. 1975; 29(4):444-7. PMC: 187001. DOI: 10.1128/am.29.4.444-447.1975. View

19.

Habermann E . 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch Pharmacol. 1974; 281(1):47-56. DOI: 10.1007/BF00500611. View

20.

BROOKS V . An intracellular study of the action of repetitive nerve volleys and of botulinum toxin on miniature end-plate potentials. J Physiol. 1956; 134(2):264-77. PMC: 1359202. DOI: 10.1113/jphysiol.1956.sp005642. View